Please login to the form below

Not currently logged in
Email:
Password:

ParagonRx appoints ex-FDA medical officer

Dr Stephen Sun joins consultancy as chief medical officer

Burlington, Massachusetts-based risk-benefit consultancy ParagonRx has appointed Dr Stephen Sun as its new chief medical officer.

Dr Sun was formerly a medical officer at US regulator the FDA and in his new role will provide regulatory and strategy advice on the optimal and safe use of new drugs and devices.

He began his pharmaceutical industry career at Organon, working in drug safety and medical knowledge management, before joining Alpharma as director of drug safety.

He was promoted to senior director of medical affairs and then after King Pharmaceuticals' acquisition of Alpharma, Dr Sun served as King's senior director of pharmacovigilance and risk management.

After gaining OTC experience at Reckitt-Benckiser, Dr Sun Sun joined the FDA as a medical officer, serving in the CDER Division of Risk Management and most recently in the Controlled Substances staff.

In his new role at ParagonRx, part of inVentiv Health, he will report directly to ParagonRx president Jeffrey Fetterman.

“The focus today is on enhanced pharmacovigilance, putting preventions in place before any regulatory body requires it,” Fetterman said. “Dr Sun's FDA experience will enrich the guidance we offer clients to assure that active risk management is at the core of developing all new products and services.”

21st August 2013

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics